Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry, Rep. Buyer Urge Appropriators To Meet User Fee Funding Goals

This article was originally published in The Gray Sheet

Executive Summary

Congress may reexamine the amount of funds allocated to the device user fee program in the omnibus FY 2003 spending bill, following the Feb. 3 release of President Bush's FY 2004 budget request, which designates only $1 mil. for premarket review activities at CDRH

You may also be interested in...



McClellan’s “Strong FDA” Is Unfazed By Device Appropriations Shortfall

FDA is assuring medical device execs that the Bush Administration is united in seeking the additional appropriations required by MDUFMA, but cannot guarantee that funding benchmarks will be met by 2004

McClellan’s “Strong FDA” Is Unfazed By Device Appropriations Shortfall

FDA is assuring medical device execs that the Bush Administration is united in seeking the additional appropriations required by MDUFMA, but cannot guarantee that funding benchmarks will be met by 2004

CDRH “LabSun” Pilot Expands MedSun Reporting Program To Labs

CDRH's Office of In Vitro Diagnostic Device Evaluation & Safety is hoping that a Medical Device Surveillance Network (MedSun) pilot geared toward IVDs will help improve the quality of adverse event information that labs send to FDA

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel